- Home
- ZBIO vs PACB Comparison
ZBIO vs PACB Comparison
Compare ZBIO & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- PACB
- Stock Information
- Founded
- ZBIO 2019
- PACB 2000
- Country
- ZBIO United States
- PACB United States
- Employees
- ZBIO N/A
- PACB N/A
- Industry
- ZBIO
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- ZBIO
- PACB Industrials
- Exchange
- ZBIO NYSE
- PACB Nasdaq
- Market Cap
- ZBIO 389.2M
- PACB 364.2M
- IPO Year
- ZBIO 2024
- PACB 2010
- Fundamental
- Price
- ZBIO $9.09
- PACB $1.15
- Analyst Decision
- ZBIO Strong Buy
- PACB Buy
- Analyst Count
- ZBIO 7
- PACB 10
- Target Price
- ZBIO $32.29
- PACB $2.45
- AVG Volume (30 Days)
- ZBIO 147.9K
- PACB 7.0M
- Earning Date
- ZBIO 05-27-2025
- PACB 05-08-2025
- Dividend Yield
- ZBIO N/A
- PACB N/A
- EPS Growth
- ZBIO N/A
- PACB N/A
- EPS
- ZBIO N/A
- PACB N/A
- Revenue
- ZBIO $5,000,000.00
- PACB $152,357,000.00
- Revenue This Year
- ZBIO N/A
- PACB $6.13
- Revenue Next Year
- ZBIO N/A
- PACB $21.55
- P/E Ratio
- ZBIO N/A
- PACB N/A
- Revenue Growth
- ZBIO N/A
- PACB N/A
- 52 Week Low
- ZBIO $5.83
- PACB $1.06
- 52 Week High
- ZBIO $26.25
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- PACB 47.60
- Support Level
- ZBIO N/A
- PACB $1.08
- Resistance Level
- ZBIO N/A
- PACB $1.23
- Average True Range (ATR)
- ZBIO 0.00
- PACB 0.06
- MACD
- ZBIO 0.00
- PACB 0.01
- Stochastic Oscillator
- ZBIO 0.00
- PACB 52.94
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.